180 related articles for article (PubMed ID: 33126941)
1. Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.
Sachdeva KS; Arora N; Solanki R; Singla R; Sarin R; Bhatnagar A; Khanna A; Atahavale A; Shridhar R; Barua SR; Parmar M; Farooq SI; Ramachandran R; Alavadi U; Swamickan R; Tonsing J; Patel Y; Singla N
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1067-1072. PubMed ID: 33126941
[No Abstract] [Full Text] [Related]
2. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
[TBL] [Abstract][Full Text] [Related]
3. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
[TBL] [Abstract][Full Text] [Related]
5. Introducing bedaquiline: experiences from the Challenge TB Project.
Edwards CG; Wares DF; Dravniece G; Gebhard A; Tiemersma E; van der Grinten E; Gidado M; van Weezenbeek K
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1046-1053. PubMed ID: 33126937
[No Abstract] [Full Text] [Related]
6. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
7. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
[TBL] [Abstract][Full Text] [Related]
8. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
[TBL] [Abstract][Full Text] [Related]
9. The Bedaquiline Donation Program: progress and lessons learned after 4 years of implementation.
Rutta E; Kambili C; Mukadi Y
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1039-1045. PubMed ID: 33126936
[TBL] [Abstract][Full Text] [Related]
10. Setting up pharmacovigilance based on available endTB Project data for bedaquiline.
Lachenal N; Hewison C; Mitnick C; Lomtadze N; Coutisson S; Osso E; Ahmed S; Leblanc G; Islam S; Atshemyan H; Nair P; Kholikulov B; Aiylchiev S; Zarli K; Adnan S; Krisnanda A; Padayachee S; Stambekova A; Sahabutdinova Y; de Guadalupe S; Moreno P; Kumsa A; Reshid A; Makaka J; Abebe S; Melikyan N; Seung KJ; Khan U; Khan P; Huerga H; Rich M; Varaine F
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1087-1094. PubMed ID: 33126944
[No Abstract] [Full Text] [Related]
11. New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India.
Das M; Mamnoon F; Mansoor H; Meneguim AC; Singh P; Shah I; Ravi S; Kalon S; Hossain FN; Ferlazzo G; Isaakidis P; Furin J; Acharya S; Thakur HP
Int J Tuberc Lung Dis; 2020 Dec; 24(12):1265-1271. PubMed ID: 33317670
[No Abstract] [Full Text] [Related]
12. Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB.
Zabsonre I; Thi SS; Cox V
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1054-1057. PubMed ID: 33126938
[TBL] [Abstract][Full Text] [Related]
13. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas.
Bernal O; Lopez R; Montoro E; Avedillo P; Westby K; Ghidinelli M
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1058-1062. PubMed ID: 33126939
[TBL] [Abstract][Full Text] [Related]
14. Introduction of bedaquiline for the treatment of drug-resistant TB in the Philippines.
Santiago MR; Garfin AMC; Balanag VM
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1063-1066. PubMed ID: 33126940
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
[TBL] [Abstract][Full Text] [Related]
16. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
[No Abstract] [Full Text] [Related]
18. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.
Sun WW; Yang M; Chen XH; Fan LC; Wu HY; Zhang SJ; Chen Y; Fan L
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):219-227. PubMed ID: 37982155
[TBL] [Abstract][Full Text] [Related]
20. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
